# Elite Pharmaceuticals Inc: financial statements, quarterly

ELTP · OTC · CIK 1053369 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Mar 31

Pages: [Overview](/companies/eltp.md) · [Financials](/companies/eltp/financials.md) · [Filings](/companies/eltp/filings.md) · [Insiders](/companies/eltp/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/eltp/financials.md?period=annual).

## Income statement

| Line item | Unit | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | Q4 FY2024 (2024-03-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q4 FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q4 FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [14.2](/filings/0001493152-24-045933.md) | [15.5](/filings/0001493152-25-006427.md) | [17.9 d](/filings/0001641172-25-017134.md) | [18.8](/filings/0001493152-25-011989.md) | [18.9](/filings/0001493152-25-023477.md) | [14.4](/filings/0001493152-26-007104.md) | [32.0 d](/filings/0001493152-26-031070.md) | [40.2](/filings/0001493152-26-037752.md) | [36.3](/filings/0001493152-25-023477.md) | [31.6](/filings/0001493152-26-007104.md) | [40.7 d](/filings/0001493152-26-031070.md) | [32.4](/filings/0001493152-26-037752.md) |
| Cost of revenue | $m | [7.7](/filings/0001493152-24-045933.md) | [8.5](/filings/0001493152-25-006427.md) | [9.8 d](/filings/0001641172-25-017134.md) | [10.3](/filings/0001493152-25-011989.md) | [10.7](/filings/0001493152-25-023477.md) | [8.2](/filings/0001493152-26-007104.md) | [14.7 d](/filings/0001493152-26-031070.md) | [13.0](/filings/0001493152-26-037752.md) | [22.2](/filings/0001493152-25-023477.md) | [18.6](/filings/0001493152-26-007104.md) | [20.0 d](/filings/0001493152-26-031070.md) | [18.8](/filings/0001493152-26-037752.md) |
| Gross profit | $m | [6.4](/filings/0001493152-24-045933.md) | [7.0](/filings/0001493152-25-006427.md) | [8.1 d](/filings/0001641172-25-017134.md) | [8.5](/filings/0001493152-25-011989.md) | [8.2](/filings/0001493152-25-023477.md) | [6.1](/filings/0001493152-26-007104.md) | [17.3 d](/filings/0001493152-26-031070.md) | [27.2](/filings/0001493152-26-037752.md) | [14.1](/filings/0001493152-25-023477.md) | [13.0](/filings/0001493152-26-007104.md) | [20.8 d](/filings/0001493152-26-031070.md) | [13.5](/filings/0001493152-26-037752.md) |
| Research and development | $m | [2.6](/filings/0001493152-24-045933.md) | [1.4](/filings/0001493152-25-006427.md) | [1.7 d](/filings/0001641172-25-017134.md) | [2.2](/filings/0001493152-25-011989.md) | [2.0](/filings/0001493152-25-023477.md) | [1.8](/filings/0001493152-26-007104.md) | [2.0 d](/filings/0001493152-26-031070.md) | [1.7](/filings/0001493152-26-037752.md) | [1.4](/filings/0001493152-25-023477.md) | [1.0](/filings/0001493152-26-007104.md) | [1.6 d](/filings/0001493152-26-031070.md) | [2.0](/filings/0001493152-26-037752.md) |
| Operating income | $m | [1.9](/filings/0001493152-24-045933.md) | [3.5](/filings/0001493152-25-006427.md) | [3.7 d](/filings/0001641172-25-017134.md) | [3.9](/filings/0001493152-25-011989.md) | [3.5](/filings/0001493152-25-023477.md) | [1.1](/filings/0001493152-26-007104.md) | [11.2 d](/filings/0001493152-26-031070.md) | [21.7](/filings/0001493152-26-037752.md) | [8.2](/filings/0001493152-25-023477.md) | [9.0](/filings/0001493152-26-007104.md) | [10.2 d](/filings/0001493152-26-031070.md) | [7.5](/filings/0001493152-26-037752.md) |
| Interest expense | $m | [0.1](/filings/0001493152-23-041124.md) | [0.1](/filings/0001493152-24-006661.md) | [0.2 d](/filings/0001493152-24-025829.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [(17.7)](/filings/0001493152-24-045933.md) | [(0.8)](/filings/0001493152-25-006427.md) | [(1.3) d](/filings/0001641172-25-017134.md) | [0.2](/filings/0001493152-25-011989.md) | [1.5](/filings/0001493152-25-023477.md) | [0.2](/filings/0001493152-26-007104.md) | [2.3 d](/filings/0001493152-26-031070.md) | [5.3](/filings/0001493152-26-037752.md) | [2.0](/filings/0001493152-25-023477.md) | [2.2](/filings/0001493152-26-007104.md) | [2.4 d](/filings/0001493152-26-031070.md) | [1.8](/filings/0001493152-26-037752.md) |
| Net income | $m | [14.9](/filings/0001493152-25-006427.md) | [0.7](/filings/0001493152-25-006427.md) | [3.3 d](/filings/0001641172-25-017134.md) | [0.6](/filings/0001493152-26-007104.md) | [(11.0)](/filings/0001493152-26-007104.md) | [(10.9)](/filings/0001493152-26-007104.md) | [17.0 d](/filings/0001493152-26-031070.md) | [(5.9)](/filings/0001493152-26-037752.md) | [13.7](/filings/0001493152-26-007104.md) | [18.6](/filings/0001493152-26-007104.md) | [18.5 d](/filings/0001493152-26-031070.md) | [5.9](/filings/0001493152-26-037752.md) |
| Diluted EPS | $ per share | [0.01](/filings/0001493152-24-045933.md) | [0.00](/filings/0001493152-25-006427.md) | not reported | [0.00](/filings/0001493152-25-011989.md) | [(0.01)](/filings/0001493152-25-023477.md) | [(0.01)](/filings/0001493152-26-007104.md) | not reported | [(0.01)](/filings/0001493152-26-037752.md) | [0.01](/filings/0001493152-25-023477.md) | [0.01](/filings/0001493152-26-007104.md) | not reported | [0.01](/filings/0001493152-26-037752.md) |
| Basic EPS | $ per share | [0.01](/filings/0001493152-24-045933.md) | [0.00](/filings/0001493152-25-006427.md) | not reported | [0.00](/filings/0001493152-25-011989.md) | [(0.01)](/filings/0001493152-25-023477.md) | [(0.01)](/filings/0001493152-26-007104.md) | not reported | [(0.01)](/filings/0001493152-26-037752.md) | [0.01](/filings/0001493152-25-023477.md) | [0.02](/filings/0001493152-26-007104.md) | not reported | [0.01](/filings/0001493152-26-037752.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | FY2024 (2024-03-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [8.7](/filings/0001493152-23-041124.md) | [5.8](/filings/0001493152-24-006661.md) | [7.1](/filings/0001493152-24-025829.md) | [8.4](/filings/0001493152-25-011989.md) | [9.6](/filings/0001493152-25-023477.md) | [8.3](/filings/0001493152-26-007104.md) | [11.3](/filings/0001493152-26-031070.md) | [21.7](/filings/0001493152-26-037752.md) | [26.6](/filings/0001493152-25-023477.md) | [21.1](/filings/0001493152-26-007104.md) | [29.8](/filings/0001493152-26-037752.md) | [38.9](/filings/0001493152-26-037752.md) |
| Current assets | $m | [34.7](/filings/0001493152-23-041124.md) | [37.2](/filings/0001493152-24-006661.md) | [40.0](/filings/0001641172-25-017134.md) | [43.2](/filings/0001493152-24-032154.md) | [45.3](/filings/0001493152-24-045933.md) | [48.0](/filings/0001493152-25-006427.md) | [57.7](/filings/0001493152-26-031070.md) | [77.9](/filings/0001493152-25-011989.md) | [85.8](/filings/0001493152-25-023477.md) | [96.8](/filings/0001493152-26-007104.md) | [112](/filings/0001493152-26-037752.md) | [114](/filings/0001493152-26-037752.md) |
| Total assets | $m | [70.7](/filings/0001493152-23-041124.md) | [74.7](/filings/0001493152-24-006661.md) | [83.7](/filings/0001641172-25-017134.md) | [87.8](/filings/0001493152-24-032154.md) | [88.2](/filings/0001493152-24-045933.md) | [90.8](/filings/0001493152-25-006427.md) | [96.4](/filings/0001493152-26-031070.md) | [111](/filings/0001493152-25-011989.md) | [117](/filings/0001493152-25-023477.md) | [126](/filings/0001493152-26-007104.md) | [138](/filings/0001493152-26-037752.md) | [140](/filings/0001493152-26-037752.md) |
| Current liabilities | $m | [19.1](/filings/0001493152-23-041124.md) | [19.2](/filings/0001493152-24-006661.md) | [13.0](/filings/0001641172-25-017134.md) | [14.0](/filings/0001493152-24-032154.md) | [12.9](/filings/0001493152-24-045933.md) | [14.7](/filings/0001493152-25-006427.md) | [11.8](/filings/0001493152-26-031070.md) | [10.8](/filings/0001493152-25-011989.md) | [10.7](/filings/0001493152-25-023477.md) | [13.2](/filings/0001493152-26-007104.md) | [17.4](/filings/0001493152-26-037752.md) | [30.4](/filings/0001493152-26-037752.md) |
| Total liabilities | $m | [25.6](/filings/0001493152-23-041124.md) | [28.3](/filings/0001493152-24-006661.md) | [26.1](/filings/0001641172-25-017134.md) | [29.6](/filings/0001493152-24-032154.md) | [40.9](/filings/0001493152-24-045933.md) | [54.3](/filings/0001493152-25-006427.md) | [42.9](/filings/0001493152-26-031070.md) | [63.7](/filings/0001493152-25-011989.md) | [55.7](/filings/0001493152-25-023477.md) | [46.1](/filings/0001493152-26-007104.md) | [39.4](/filings/0001493152-26-037752.md) | [34.8](/filings/0001493152-26-037752.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [45.1](/filings/0001493152-25-006427.md) | [46.4](/filings/0001493152-25-006427.md) | [57.6](/filings/0001493152-26-031070.md) | [58.3](/filings/0001493152-26-007104.md) | [47.3](/filings/0001493152-26-007104.md) | [36.4](/filings/0001493152-26-007104.md) | [53.5](/filings/0001493152-26-037752.md) | [47.7](/filings/0001493152-26-037752.md) | [61.6](/filings/0001493152-26-007104.md) | [80.3](/filings/0001493152-26-007104.md) | [98.9](/filings/0001493152-26-037752.md) | [105](/filings/0001493152-26-037752.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue, us-gaap:Cash
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | Q4 FY2024 (2024-03-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q4 FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q4 FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(0.2) d](/filings/0001493152-24-045933.md) | [(2.4) d](/filings/0001493152-25-006427.md) | [2.1 d](/filings/0001641172-25-017134.md) | [3.1](/filings/0001493152-25-011989.md) | [1.5 d](/filings/0001493152-25-023477.md) | [(1.1) d](/filings/0001493152-26-007104.md) | [3.9 d](/filings/0001493152-26-031070.md) | [14.8](/filings/0001493152-26-037752.md) | [5.1 d](/filings/0001493152-25-023477.md) | [(5.3) d](/filings/0001493152-26-007104.md) | [9.1 d](/filings/0001493152-26-031070.md) | [10.1](/filings/0001493152-26-037752.md) |
| Capital expenditure | $m | not reported | not reported | [0.4 d](/filings/0001641172-25-017134.md) | [0.8](/filings/0001493152-25-011989.md) | [0.1 d](/filings/0001493152-25-023477.md) | [0.0 d](/filings/0001493152-26-007104.md) | [0.8 d](/filings/0001493152-26-031070.md) | [0.2](/filings/0001493152-26-037752.md) | [0.1 d](/filings/0001493152-25-023477.md) | [0.2 d](/filings/0001493152-26-007104.md) | [0.4 d](/filings/0001493152-26-031070.md) | [0.8](/filings/0001493152-26-037752.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q2 FY2023 (2022-09-30) | Q3 FY2023 (2022-12-31) | Q1 FY2024 (2023-06-30) | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [1,012](/filings/0001493152-23-041124.md) | [1,014](/filings/0001493152-24-006661.md) | [1,015](/filings/0001493152-24-032154.md) | [1,019](/filings/0001493152-24-045933.md) | [1,024](/filings/0001493152-25-006427.md) | [1,076](/filings/0001493152-25-011989.md) | [1,068](/filings/0001493152-25-023477.md) | [1,068](/filings/0001493152-26-007104.md) | [1,068](/filings/0001493152-26-037752.md) | [1,142](/filings/0001493152-25-023477.md) | [1,141](/filings/0001493152-26-007104.md) | [1,129](/filings/0001493152-26-037752.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 1,077,136,442 at 2026-08-13, from the cover of the [10-Q filed 2026-08-13](/filings/0001493152-26-037752.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:31 ET. No prices; not investment advice.